Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells

BACKGROUND: Tamoxifen (TAM) is the eminent first-line drug for endocrine therapy of hormone receptor positive premenopausal breast cancer and reduces the risk of recurrence by ∼50%. However, many patients developed TAM resistance and their diseases recurred. Our previous study on transcriptome profi...

Descripción completa

Detalles Bibliográficos
Autores principales: Men, Xin, Su, Mengyang, Ma, Jun, Mou, Yueyang, Dai, Penggao, Chen, Chao, Cheng, Xi An
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989118/
https://www.ncbi.nlm.nih.gov/pubmed/33745390
http://dx.doi.org/10.1177/15330338211004916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989118/
https://www.ncbi.nlm.nih.gov/pubmed/33745390
http://dx.doi.org/10.1177/15330338211004916

Ejemplares similares